An Open-Label, Expanded Access Protocol for Amifampridine Phosphate (3,4- Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome and Downbeat Nystagmus
A study for patients with Lambert-Eaton Myasthenic Syndrome (LEMS) using study drug Amifampridine Phosphate
Sponsor: Catalyst Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAO6308
U.S. Govt. ID: NCT02189720
Contact: Jacqueline Scoon: 212-305-6035 /
Additional Study Information: This study is for patients with Lambert-Eaton Myasthenic Syndrome (LEMS). The purpose of this study is to provide doctors and their patients access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus until the product becomes commercially available. The secondary purpose of the study is to assess the long-term safety of amifampridine phosphate in patents.
This study is closed
Thomas Brannagan, MD
Do You Qualify?
Do you have a confirmed diagnosis of LEMS, CMS or downbeat nystagmus? Yes No
Do you have a history of epilepsy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Jacqueline Scoon